Concepedia

Author

Srđan Verstovšek

The University of Texas MD Anderson Cancer CenterORCID

Also Known As

Matthew Cooperberg, S Verstovsek, S. VERSTOVSEK, S. Verstovsek, S. Verstovšek, Srdan Verstovsek, Srdan Verstovšek, Srđan Verstovšek, Verstovsek S, Verstovsek, S.

1.6K

Publications

57.4K

Citations

114

H-Index

172

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterMayo Clinic in ArizonaIncyte (United States)Guy's and St Thomas' NHS Foundation TrustHôpital Saint-Louis
SV

About

Srđan Verstovšek is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, hematology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

57

189

11.6K

2

Health Sciences

33

65

3.9K

3

Natural Sciences

3

3

275

4

Public Health

3

3

146

5

Allergy

3

3

306

Srđan Verstovšek

×

542

Publications

43.7K

Citations

106

H-Index

YearCitations

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib,

New England Journal of Medicine

2012

2K

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

Srđan Verstovšek, Hagop M. Kantarjian, Ruben A. Mesa,

New England Journal of Medicine

2010

1.2K

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

Ayalew Tefferi, Jüergen Thiele, Attilio Orazi,

Blood

2007

857

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer,

New England Journal of Medicine

2015

851

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Tiziano Barbui, Giovanni Barosi, Gunnar Birgegård,

Journal of Clinical Oncology

2011

825

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Alfonso Quintás‐Cardama, Kris Vaddi, Phillip Liu,

Blood

2010

813

Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia

Deborah A. Thomas, Stefan Faderl, Susan O’Brien,

Cancer

2006

562

Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia

Guillermo Garcia‐Manero, Hagop M. Kantarjian, Blanca Sánchez‐González,

Blood

2006

467

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Taghi Manshouri,

Journal of Clinical Oncology

2009

412

Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

Deborah A. Thomas, Susan O’Brien, Stefan Faderl,

Journal of Clinical Oncology

2010

409

Page 1